230 related articles for article (PubMed ID: 11878407)
1. Ritonavir/saquinavir plus one nucleoside reverse transcriptase inhibitor (NRTI) versus indinavir plus two NRTIs in protease inhibitor-naive HIV-1-infected adults (IRIS study).
Florence E; Dreezen C; Desmet P; Smets E; Fransen K; Vandercam B; Pelgrom J; Clumeck N; Colebunder R
Antivir Ther; 2001 Dec; 6(4):255-62. PubMed ID: 11878407
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.
Greenberg RN; Feinberg J; Goodrich J; Pilson RS; Siemon-Hryczyk P
Antivir Ther; 2003 Feb; 8(1):37-42. PubMed ID: 12713062
[TBL] [Abstract][Full Text] [Related]
5. The danish protease inhibitor study: a randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection.
Katzenstein TL; Kirk O; Pedersen C; Lundgren JD; Nielsen H; Obel N; Nielsen C; Mathiesen LR; Gerstoft J
J Infect Dis; 2000 Sep; 182(3):744-50. PubMed ID: 10950767
[TBL] [Abstract][Full Text] [Related]
6. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy.
Rockstroh JK; Altfeld M; Kupfer B; Kaiser R; Fätkenheuer G; Salzberger B; Schneweis KE; Spengler U
Eur J Med Res; 1999 Jul; 4(7):271-4. PubMed ID: 10425264
[TBL] [Abstract][Full Text] [Related]
7. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
8. First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results.
Voigt E; Wickesberg A; Wasmuth JC; Gute P; Locher L; Salzberger B; Wöhrmann A; Adam A; Weitner L; Rockstroh JK
HIV Med; 2002 Oct; 3(4):277-82. PubMed ID: 12444946
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of HIV infections and AIDS with protease inhibitor and two nucleoside analogs].
Jensen-Fangel S; Larsen L; Thomsen HF; Nielsen LP; Black FT; Obel N
Ugeskr Laeger; 1999 Mar; 161(12):1751-4. PubMed ID: 10210974
[TBL] [Abstract][Full Text] [Related]
10. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
[TBL] [Abstract][Full Text] [Related]
11. Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.
Bucher HC; Bichsel M; Taffé P; Furrer H; Telenti A; Hirschel B; Weber R; Bernasconi E; Vernazza P; Minder C; Battegay M;
HIV Med; 2002 Oct; 3(4):247-53. PubMed ID: 12444942
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of protease inhibitor based antiretroviral combination therapy--a prospective cohort study.
Salzberger B; Rockstroh J; Wieland U; Franzen C; Schwenk A; Jütte A; Hegener P; Cornely O; Mörchen C; Gaensicke T; Diehl V; Fätkenheuer G
Eur J Med Res; 1999 Nov; 4(11):449-55. PubMed ID: 10585299
[TBL] [Abstract][Full Text] [Related]
13. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
14. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.
Lichterfeld M; Nischalke HD; Bergmann F; Wiesel W; Rieke A; Theisen A; Fätkenheuer G; Oette M; Carls H; Fenske S; Nadler M; Knechten H; Wasmuth JC; Rockstroh JK
HIV Med; 2002 Jan; 3(1):37-43. PubMed ID: 12059949
[TBL] [Abstract][Full Text] [Related]
16. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
Jahnke N; Seminari E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 1999; 4(3):151-6. PubMed ID: 12731754
[TBL] [Abstract][Full Text] [Related]
18. Patients failing saquinavir therapy require an early change to indinavir before HIV-1 viral load reaches high levels.
Dronda F; Pérez-Elías MJ; Antela A; Casado JL; Martí-Belda P; Cobo J
Antivir Ther; 1999; 4(2):117-21. PubMed ID: 10682157
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
[TBL] [Abstract][Full Text] [Related]
20. Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.
Katner HP; Paar DP; Nadler JP; Jensen EH; Wilson HM; Finn TS; Petruschke RA; Zeldin RK
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):483-7. PubMed ID: 12473836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
